NCT01769183

Squalamine for the Treatment in Proliferative Diabetic Retinopathy

Topical Squalamine in the Treatment of Retinal Neovascularization From Proliferative Diabetic Retinopathy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Elman Retina Group · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the efficacy in the use of topical Squalamine Lactate Ophthalmic Solution, 0.2% in the treatment of retinal neovascularization resulting from proliferative diabetic retinopathy.

Conditions

• Retinal Neovascularization

Interventions

Type	Name	Description
DRUG	Squalamine Lactate ophthalmic solution 0.2%	Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.

Timeline

• Start date: 2013-02-01
• Primary completion: 2014-08-01
• Completion: 2014-08-01
• First posted: 2013-01-16
• Last updated: 2015-02-10

Locations

1 site across 1 country: United States